2013
DOI: 10.1111/cen.12189
|View full text |Cite
|
Sign up to set email alerts
|

Glucocorticoid‐induced osteoporosis: lessons from Cushing's syndrome

Abstract: SummaryGlucocorticoid-induced osteoporosis (GIO) is the most frequent form of secondary bone disorders. Most of our knowledge on its pathogenesis and treatment has been obtained by investigating patients treated with exogenous glucocorticoids. This review will focus on the bone disorder in endogenous Cushing's syndrome, updating recent advances in its pathophysiology, diagnostic aspects and the various predictors which are important in determining bone mineral density (BMD) and fracture risk. We now know stron… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

4
77
0
2

Year Published

2014
2014
2021
2021

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 74 publications
(83 citation statements)
references
References 89 publications
(264 reference statements)
4
77
0
2
Order By: Relevance
“…Interestingly, in that study, duration of GC replacement after treatment for CS was independently associated with reduced BMD at lumbar spine. A similar association was observed in our study, i.e., GC replacement therapy was independently associated with reduced total BMD and BMD at lumbar spine, probably explained by the fact that the effects of GCs on the skeletal tissue is most prominent on trabecular bone such as in the lumbar spine (27). The median hydrocortisone dose used in the GC-treated patients in our study was 25 mg/day.…”
Section: Discussionsupporting
confidence: 90%
“…Interestingly, in that study, duration of GC replacement after treatment for CS was independently associated with reduced BMD at lumbar spine. A similar association was observed in our study, i.e., GC replacement therapy was independently associated with reduced total BMD and BMD at lumbar spine, probably explained by the fact that the effects of GCs on the skeletal tissue is most prominent on trabecular bone such as in the lumbar spine (27). The median hydrocortisone dose used in the GC-treated patients in our study was 25 mg/day.…”
Section: Discussionsupporting
confidence: 90%
“…Adjustments for more than only a few biological plausible covariates (fulfilling respective model inclusion criteria) may really be required to “winkle out” a specific direct (not mediated), but physiologically moderate predictor action, which, in case of the GC–bone relationship, has been biologically proven in cell and tissue experiments …”
Section: Discussionmentioning
confidence: 99%
“…The scant fracture data suggest that the increased symptomatic fracture risk disappears after curing CS, similar to that seen in exogenous glucocorticoid-induced osteoporosis (204,206). It is not clear whether complete normalization occurs because the expected BMD for a given person cannot be predicted (8,173,200). We recommend a detailed fracture assessment, evaluating BMD at the spine and hip, obtaining lateral morphometric imaging of the spine, adequate calcium and vitamin D intake, avoidance of excessive glucocorticoid supplementation, and personalized long-term follow-up based on the results of bone evaluation.…”
Section: Osteoporosismentioning
confidence: 92%
“…Osteoporosis results from direct effects of cortisol on bone cells and indirect events such as glucocorticoid-induced hypogonadism, secondary hyperparathyroidism, GH deficiency, and reduced bone strain due to myopathy (200). However, the prevalence of fractures is not known (201).…”
Section: Osteoporosismentioning
confidence: 99%